



Medicinal Chemistry of Adenosine Receptor Antagonists

Guest Editors:

Dr. Catia Lambertucci

Università degli Studi di
Camerino, Camerino, Italy

Dr. Rosaria Volpini

Scuola di Scienze del Farmaco e
dei Prodotti della Salute,
Università degli Studi di
Camerino, Via S. Agostino 1,
62032 Camerino, Italy

Deadline for manuscript
submissions:

closed (20 December 2021)

Message from the Guest Editors

Dear Colleagues,

This is an invitation to submit your research results in the field of medicinal chemistry of the adenosinergic system.

Adenosine (Ado) is an extracellular signalling molecule which, by activating specific receptors, is involved in a variety of physiological and pathological processes, including central and peripheral nervous system functions, modulation of cardiovascular and respiratory activity, regulation of immune systems in humans and other species. Ado receptors (ARs) are G protein-coupled receptors classified as A₁, A_{2A}, A_{2B}, and A₃ subtypes, which are expressed throughout the body with different tissue/organ distribution and signalling.

This Special Issue aims to provide readers with recent advances in the medicinal chemistry of AR antagonists. The topics proposed include molecules endowed with AR antagonist properties and designed as pharmacological tools and diagnostic probes, their synthesis, biological evaluation and pharmacokinetic properties. Molecular modelling studies are also welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com